TRANSFORMING HEALTHCARE THROUGH CELLULAR THERAPIES

HEALTHCARE GROUP WITH CLINICAL-STAGE PROJECTS

SWISS-BASED GROUP WITH A GLOBAL SCOPE

BUILT ON PRIVILEGED ACCESS TO WORLD-CLASS RESEARCH

MedXCell SA is a Swiss specialist healthcare group with clinical-stage projects. It is dedicated to transforming healthcare through the development and production of affordable and accessible new therapies utilizing the unique healing powers of living cells. MedXCell is devoted to the development and the manufacturing of innovative off-the-shelf cellular therapies offering state-of-the-art, cost-effective and safe solutions for a wide range of patient needs. The company enjoys a close relationship with academic research, most notably with the Institute for Regenerative Medicine and Biotherapy of Montpellier, France.

ABOUT US

0
Affiliate Companies
0
Technology Areas
+0
Employees

Our mission is to harness the power of cellular therapies to make lives better

GROUP FORMATION TIMELINE

2015
Clinical Service Provider
Premium and personalised cell therapy services provider of unregulated autologous cell therapy oriented towards privileged customers
2015
2016
MedXCell SA
Formation of MedXCell SA with the inspiration to develop affordable drugs out of cells
2016
2017
Partnership
Partnership with the CHU of Montpellier providing MedXCell with access to world-class research results
2017
2018
MedXCell Science
Formation of MedXCell Science to specialise in product development utilizing mesenchymal cells (MSCs). CHU of Montpellier as shareholder of the company (first time in French History)
2018
2020
ADIPOA
Exclusive commercial rights of ADIPOA vest into MedxCell Science. First clinical product, already in phase 2 studies.
2020
2020
MedXCell NKar
Formation of MedXCell NKar to specialise in cellular immunotherapy using Natural Killer (NK) cells
2020

MEDXCELL TECHNOLOGIES

The MedXCell Group has assembled a unique, powerful and comprehensive portfolio of functional cells technologies, underpinned by a philosophy of using the natural functions of normal cell types to achieve results with high efficacy and safety.

MESENCHYMAL STROMAL CELLS (MSCs)

for treating skeletal and mechanical tissue pathology and for modulating undesirable inflammation and immune mechanisms in injured tissues.

NATURAL KILLER CELLS (NK)

for hunting and elimination of undesirable and abnormal cells that cause pathology such as cancer cells, virus infected or virus vulnerable cells or aberrant immune cells

INDUCED PLURIPOTENT STEM CELLS (iPSCs)

for generating a range of functional cells from simple sources

CELL PRODUCTS

Organelles, secretory vesicles, molecules produced by cells in culture and administered to patients for specific tasks e.g. neutralizing virus’s, or identifying (labelling) aberrant cells to be targeted by therapeutic cells.

THERAPEUTIC FOCUS

MUSCULOSKELETAL DISEASES

CANCERS & AUTO-IMMUNE DISEASES

GROUP PIPELINE

Knee Osteoarthritis
Phase 2
Next potential milestone:

Phase 2b/3 to start H2 2021

Other Joints Osteoarthritis (Hip, Back, ...)
Pre-clinical

Next potential milestone:

Multiple phase 2 to start H1 2022
Central Nervous System Lymphoma
Pre-clinical

Next potential milestone:

IND Q1 2022

Acute Myeloid Leukemia
Pre-clinical

Next potential milestone:

IND Q4 2022

Solid Tumors
Pre-clinical

Next potential milestone:

IND Q1 2023

TEAM

MANAGEMENT

Laurent ZBINDEN

CEO

Lionel BRODARD

CFO

Alan COOKSON

CTO

Patrice LUTHI

COO

Claire GONDEAU

CSO – MedXCell Science

Jessy PRESUMEY

R&D – MedXCell NKar

Marc CRITON

BDO

SCIENTIFIC COMMITTEE

Prof. Christian JORGENSEN

Prof. John DE VOS

Prof. Danièle NOEL

Dr Martin VILLALBA

Dr Pierre Martineau

Dr Bruno Robert

Dr Javier HERNANDEZ

NEWS

MEDXCELL IN THE PRESS
Previous
Next

PRESS RELEASES